Dysport

World

adminNovember 18, 2020
6

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)

Lausanne, Switzerland: Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…
Read More »
Technology

adminOctober 10, 2020
16

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Lausanne, Switzerland: Galderma today announced the presentation of data from clinical trials of its aesthetic solutions and pipeline in five…
Read More »